Logo

Incyte, Epoch Biosciences Enter Licensing and Development Deal

Oct 10, 2001

SAN FRANCISCO, Oct. 10 – Incyte Genomics has enter a licensing and development alliance with molecular tools manufacturer Epoch Biosciences, the companies announced Wednesday.

The terms include Epoch’s licensing Palo Alto-based Incyte’s LifeSeq Gold and ZooSeq databases for development of oligonucleotide probes and Incyte naming Epoch the “preferred provider” of custom oligonucleotide probes in addition to receiving Epoch Eclipse Probe Systems for use in internal development.

Financial details of the agreement were not disclosed.

“Epoch is recognized for its leading technologies related to the development of enhanced genetic analysis tools,” Roy A. Whitfield, CEO of Incyte, said in a statement. “This alliance with Epoch leverages their probe design and manufacturing capabilities and provides our users of LifeSeq Gold with a source of reliable probes to enhance their genetic analysis and research efforts.”

Epoch Biosciences is based in Bothell, Wash.

Breaking News
The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.